Medicare can pay for obesity drugs like Wegovy in certain heart patients
Time:2024-05-21 07:55:47 Source:businessViews(143)
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Previous:Liverpool confirms Arne Slot as Jurgen Klopp's replacement
Next:College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
You may also like
- Analysis: Larson enters conversation with Verstappen as best drivers in the world
- The Met Gala's flowery theme went in all directions
- Prada focuses generational transition on artisans, expanding production and workforce in Italy
- Eurovision viewers SLAM 'epilepsy
- Shohei Ohtani's first walk
- Mexico hit by hours of rolling blackouts due to high temperatures and low power generation
- Zendaya displays her stylish off
- Mexico tightens travel rules on Peruvians in a show of visa diplomacy to slow migration to US
- NBA playoffs: Edwards leads Wolves to 98